Craig B

The COVID-19 pandemic and wildfire smoke shrouding the skies over the East Coast this summer have drawn more attention to indoor air quality, leading…

Despite many delays and lawsuits from affected stakeholders, OSHA announced today that it will expand the types of OSHA forms employers must submit…

OSHA announced last week a notice of proposed rulemaking to revise the personal protective equipment standard for the construction industry. A…

Despite recent advances in both coupled fire modeling and measurement techniques to sample the fire environment, the fire–atmosphere coupling mechanisms that lead to fast propagating wildfires remain poorly understood. This knowledge gap adversely affects fire management when wildland fires propagate unexpectedly rapidly and shift direction due to the fire impacts on local wind conditions. In this work, we utilized observational data from the FireFlux2 prescribed burn and numerical simulations performed with a coupled fire–atmosphere model WRF-SFIRE to assess the small-scale impacts of fire on local micrometeorology under moderate wind conditions (10–12 m/s). The FireFlux2 prescribed burn provided a comprehensive observational dataset with in situ meteorological observations as well as IR measurements of fire progression. To directly quantify the effects of fire–atmosphere interactions, two WRF-SFIRE simulations were executed. One simulation was run in a two-way coupled mode in which the heat and moisture fluxes emitted from the fire were injected into the atmosphere, and the other simulation was performed in a one-way coupled mode for which the atmosphere was not affected by the fire. The difference between these two simulations was used to analyze and quantify the fire impacts on the atmospheric circulation at different sections of the fire front. The fire-released heat fluxes resulted in vertical velocities as high as 10.8 m/s at the highest measurement level (20 m above ground level) gradually diminishing with height and dropping to 7.9 m/s at 5.77 m. The fire-induced horizontal winds indicated the strongest fire-induced flow at the lowest measurement levels (as high as 3.3 m/s) gradually decreasing to less than 1 m/s at 20 m above ground level. The analysis of the simulated flow indicates significant differences between the fire-induced circulation at the fire head and on the flanks. The fire-induced circulation was much stronger near the fire head than at the flanks, where the fire did not produce particularly strong cross-fire flow and did not significantly change the lateral fire progression. However, at the head of the fire the fire-induced winds blowing across the front were the strongest and significantly accelerated fire progression. The two-way coupled simulation including the fire-induced winds produced 36.2% faster fire propagation than the one-way coupled run, and more realistically represented the fire progression.

To increase enforcement concerning workplace violence incidents, OSHA published a Standard Interpretation Letter concluding injuries resulting from…

Quantification of climate warming in California using machine learning shows increased daily wildfire growth risk by 25%, with an expected increase of 59% and 172% in 2100, for low- and very-high-emissions scenarios, respectively.

Michael P. Kahn, Craig B. Bleifer and Caitlin E. Olwell of Akin discuss the interplay between patent law, court procedures and regulatory regimes in light of the requirements and guidance on the Inflation Reduction Act.

The U.S. Department of Labor recently announced that OSHA has launched a new initiative focused on enhancing enforcement and providing compliance…

The impending federal government shutdown will suspend many enforcement and consultation functions of the United States Department of Labor…

ABSTRACT Objective: Some individuals with attention-deficit/hyperactivity disorder (ADHD) may not tolerate or adequately respond to currently available treatments. This study examined whether solriamfetol could have a favorable pattern of effects and tolerability as a treatment for ADHD in adults. Methods: Sixty adults with DSM-5 ADHD participated from August 2021 through January 2023 in a remotely conducted, randomized, double-blind, placebo-controlled, 6-week dose-optimization trial of 75 mg or 150 mg of solriamfetol. Measures included the Adult ADHD Investigator Symptom Rating Scale (AISRS), which was our primary outcome measure, as well as the Clinical Global Impressions scale (CGI), vital signs, the Global Assessment of Functioning (GAF), the Behavior Rating Inventory of Executive Function-Adult Form (BRIEF-A), the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), and a modified Adult ADHD Self-Report Scale (MASRS). Results: Solriamfetol was well tolerated, with no significant effect on mean heart rate (+3.7 vs +2.2 bpm, P = .5609), systolic blood pressure (+2.4 vs +1.5 mm Hg, P = .6474), or diastolic blood pressure (+1.1 vs +1.5 mm Hg, P = .8117). There was no statistically significant treatment effect on occurrence of adverse events. Compared to individuals on placebo, individuals on solriamfetol treatment experienced adverse events at a rate of at least 10 percentage points higher in the categories of decreased appetite, headache, gastrointestinal, insomnia, increased energy, cardiovascular, and neurologic. Compared to individuals on placebo, by study endpoint, a greater proportion of individuals in the treatment group met the a priori–defined treatment response (CGI score indicating much or very much improved and AISRS score reduced ≥ 25%: 45% vs 6.9%, P = .0020); those treated with solriamfetol also had greater improvement in total AISRS scores by week 3 through week 6 (P = .0012; week 6 effect size = 1.09). Significantly more solriamfetol-treated adults than placebo-treated adults had 0.5–standard deviation improvement in T-score on the BRIEF-A Global Executive Composite (P = .0173); those treated with solriamfetol also had greater mean change in GAF score (−4.8 vs −0.3, P = .0006) and greater mean MASRS total score change (P = .0047; effect size = 1.23). Mean ESS score improved more with solriamfetol than with placebo (P = .0056), but this difference did not predict AISRS response (P = .3735). There was no significant association between solriamfetol and change in PSQI scores. Conclusions: Solriamfetol may be a novel and effective treatment for the management of ADHD in adults. Further replication in larger trials is indicated. Trial Registration: ClinicalTrials.gov identifier: NCT04839562 J Clin Psychiatry 2023;84(6):23m14934 Author affiliations are listed at the end of this article.